



UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: March 10, 2022

Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg	5:02 PM		
A. Minutes from previous meetings	G. Shutzberg	Review of Minutes from December 16, 2021	Minutes reviewed, approved	Yes
A. Introduction - P&T Committee Updates	A. Volberg	Review of EQulPP Pharmacy Quality Solutions: Presented program overview of how Unitedhealthcare works in partnership with CMS to develop pharmacy quality measurements for programs such as STARs and HEDIS.	Non voting item	Yes
	Comment:	Discussion held regarding the geographic coverage area and patient status as to who is able to participate. Committee requesting follow-up reporting which will be brought back to a later meeting.		
B. Formulary Review - New Drugs	C. Lichtinger	Livmarli		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	C. Lichtinger	Bylvay		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	C. Lichtinger	Elyxyb		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	M. Reisman	Exkivity		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	M. Reisman	Invega Hafyera		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	Comment:	Discussion held regarding the patient population. Suggestion made to only treat well controlled established patients to avoid side effects.		
	M. Reisman	Lybalvi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	C. Lichtinger	Opzelura		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	M. Reisman	Qulipta		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	Comment:	Discussion held regarding the clinical trial statistics.		

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
B. Formulary Review - New Drugs (cont.)	M. Reisman	Scemblix		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	M. Reisman	Skytrofa		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	Comment:	Discussion held regarding patients with needle-phobia and if they can bypass preferred alternatives since Skytrofa requires less frequent dosing than Zomacton.		
	C. Lichtinger	Tavneos		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	M. Reisman	Tyrvaya		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	Comment:	Discussion held regarding the delivery system of the medication.		
	C. Lichtinger	Vuity		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
C. Lichtinger	Welireg			
	Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0	
C. Formulary Review - New Drugs- Medical	M. Reisman	Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		Ryplazim		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
		Nexviazyme		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
		Tivdak		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
		Susvimo		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
D. Formulary Review - Drugs Evaluated Per Grid	C. Lichtinger	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	12:0
E. Clinical Guidelines	C. Lichtinger	Clinical Guideline Review	Yes/No	Yes
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	12:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	12:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	12:0
F. Quality Monitoring	M. Theys/M. Reisman	Confirm Review of Quality Data	Yes/No	Yes
	M. Theys	DUR Review		
	G. Johnson/G. Shutzberg	COVID Dashboard		
	M. Reisman	Top 25 Drugs by Spend and Volume – 4th Quarter 2021		
	M. Reisman	Top 10 Drugs Requested - Approvals and Denials – 4th Quarter 2021		
	M. Reisman	Grievances and Appeals Data – 4th Quarter 2021		
	M. Reisman	Inter-Rater Reliability (IRR) – 4th Quarter 2021 • Pharmacists		
Adjournment	G. Shutzberg		7:01 PM	
Comments: • Committee member documented the following question on their tally. Suggest showing top 10 drugs with QTC (interval edits). Would a newsletter be helpful?				

Respectfully Submitted to the Committee,



James P. Hancovsky, M.S.I.A., R.Ph.
Chief Pharmacy Officer, UHC C&S